This company listing is no longer active
TAL Stock Overview
A science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Taro Pharmaceutical Industries Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.00 |
| 52 Week High | US$40.00 |
| 52 Week Low | US$30.80 |
| Beta | 0.56 |
| 1 Month Change | 1.52% |
| 3 Month Change | 3.09% |
| 1 Year Change | 12.99% |
| 3 Year Change | -34.43% |
| 5 Year Change | -47.19% |
| Change since IPO | 6.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| TAL | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.5% | 1.4% | 0.5% |
| 1Y | 13.0% | -16.3% | 7.2% |
Return vs Industry: TAL exceeded the German Pharmaceuticals industry which returned -15.7% over the past year.
Return vs Market: TAL exceeded the German Market which returned 3.1% over the past year.
Price Volatility
| TAL volatility | |
|---|---|
| TAL Average Weekly Movement | 1.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TAL has not had significant price volatility in the past 3 months.
Volatility Over Time: TAL's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 1,554 | Uday Baldota | www.taro.com |
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.
Taro Pharmaceutical Industries Ltd. Fundamentals Summary
| TAL fundamental statistics | |
|---|---|
| Market cap | €1.51b |
| Earnings (TTM) | €50.21m |
| Revenue (TTM) | €586.46m |
30.0x
P/E Ratio2.6x
P/S RatioIs TAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TAL income statement (TTM) | |
|---|---|
| Revenue | US$629.18m |
| Cost of Revenue | US$324.20m |
| Gross Profit | US$304.98m |
| Other Expenses | US$251.11m |
| Earnings | US$53.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.43 |
| Gross Margin | 48.47% |
| Net Profit Margin | 8.56% |
| Debt/Equity Ratio | 0% |
How did TAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/24 04:55 |
| End of Day Share Price | 2024/06/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Taro Pharmaceutical Industries Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Randall Stanicky | Goldman Sachs |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Kenneth Cacciatore | TD Cowen |